The Multipotential of Leucine-Rich α-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma
Abstract Leucine-rich α-2 glycoprotein 1 (LRG1) is a diagnostic marker candidate for glioblastoma. Although LRG1 has been associated with angiogenesis, it has been suggested that its biomarker role differs depending on the type of tumor. In this study, a clinicopathological examination of LRG1’s rol...
Gespeichert in:
| Veröffentlicht in: | Journal of neuropathology and experimental neurology 2020-08, Vol.79 (8), p.873-879 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 879 |
|---|---|
| container_issue | 8 |
| container_start_page | 873 |
| container_title | Journal of neuropathology and experimental neurology |
| container_volume | 79 |
| creator | Furuta, Takuya Sugita, Yasuo Komaki, Satoru Ohshima, Koichi Morioka, Motohiro Uchida, Yasuo Tachikawa, Masanori Ohtsuki, Sumio Terasaki, Tetsuya Nakada, Mitsutoshi |
| description | Abstract
Leucine-rich α-2 glycoprotein 1 (LRG1) is a diagnostic marker candidate for glioblastoma. Although LRG1 has been associated with angiogenesis, it has been suggested that its biomarker role differs depending on the type of tumor. In this study, a clinicopathological examination of LRG1’s role as a biomarker for glioblastoma was performed. We used tumor tissues of 155 cases with diffuse gliomas (27 astrocytomas, 14 oligodendrogliomas, 114 glioblastomas). The immunohistochemical LRG1 intensity scoring was classified into 2 groups: low expression and high expression. Mutations of IDH1, IDH2, and TERT promoter were analyzed through the Sanger method. We examined the relationship between LRG1 expression level in glioblastoma and clinical parameters, such as age, preoperative Karnofsky performance status, tumor location, extent of resection, O6-methylguanine DNA methyltransferase promoter, and prognosis. LRG1 high expression rate was 41.2% in glioblastoma, 3.7% in astrocytoma, and 21.4% in oligodendroglioma. Glioblastoma showed a significantly higher LRG1 expression than lower-grade glioma (p = 0.0003). High expression of LRG1 was an independent favorable prognostic factor (p = 0.019) in IDH-wildtype glioblastoma and correlated with gross total resection (p = 0.002) and the tumor location on nonsubventricular zone (p = 0.00007). LRG1 demonstrated multiple potential as a diagnostic, prognostic, and regional biomarker for glioblastoma. |
| doi_str_mv | 10.1093/jnen/nlaa058 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2423060856</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jnen/nlaa058</oup_id><sourcerecordid>2423060856</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3646-e8bb27ebbc0515bc06a8ff77c379fb42526cd35614aecf58e27686736e98e9a63</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EotPCjjWKxAIWmDr-97KM6IA0CAmVdeS4N8RTjz3Yiao-Fi_CM-FoBhYs2Njy0XePju9B6EVL3rXEsMtdhHgZg7VE6Edo1QrBsRRKP0YrQijFjEhzhs5L2RFCDDH8KTpjVHKlDVshfzNC83kOkz-kCeLkbWjS0Gxhdj4C_urd2Pz6iWmzCQ8uHXKFfGzaxpbGNuvgo6-qncYU0nfv6vB7n_Y230FebDbBpz7YMlXtGXoy2FDg-em-QN-uP9ysP-Ltl82n9dUWOya5xKD7niroe0dEK-oprR4GpRxTZug5FVS6WyZkyy24QWigSmqpmASjwVjJLtCbo28N-2OGMnV7XxyEYCOkuXSU07oSosWCvvoH3aU5x5quUoopRTU3lXp7pFxOpWQYukP29Y8PXUu6pYJuqaA7VVDxlyfTud_D7V_4z84rwI_AfQoT5HIX5nvI3Qg2TGNXSyKCKIopoYTo-sKLtIR9fRxL8-H_CX4DC1aglA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473772849</pqid></control><display><type>article</type><title>The Multipotential of Leucine-Rich α-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma</title><source>MEDLINE</source><source>Oxford University Press Journals Current</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Furuta, Takuya ; Sugita, Yasuo ; Komaki, Satoru ; Ohshima, Koichi ; Morioka, Motohiro ; Uchida, Yasuo ; Tachikawa, Masanori ; Ohtsuki, Sumio ; Terasaki, Tetsuya ; Nakada, Mitsutoshi</creator><creatorcontrib>Furuta, Takuya ; Sugita, Yasuo ; Komaki, Satoru ; Ohshima, Koichi ; Morioka, Motohiro ; Uchida, Yasuo ; Tachikawa, Masanori ; Ohtsuki, Sumio ; Terasaki, Tetsuya ; Nakada, Mitsutoshi</creatorcontrib><description>Abstract
Leucine-rich α-2 glycoprotein 1 (LRG1) is a diagnostic marker candidate for glioblastoma. Although LRG1 has been associated with angiogenesis, it has been suggested that its biomarker role differs depending on the type of tumor. In this study, a clinicopathological examination of LRG1’s role as a biomarker for glioblastoma was performed. We used tumor tissues of 155 cases with diffuse gliomas (27 astrocytomas, 14 oligodendrogliomas, 114 glioblastomas). The immunohistochemical LRG1 intensity scoring was classified into 2 groups: low expression and high expression. Mutations of IDH1, IDH2, and TERT promoter were analyzed through the Sanger method. We examined the relationship between LRG1 expression level in glioblastoma and clinical parameters, such as age, preoperative Karnofsky performance status, tumor location, extent of resection, O6-methylguanine DNA methyltransferase promoter, and prognosis. LRG1 high expression rate was 41.2% in glioblastoma, 3.7% in astrocytoma, and 21.4% in oligodendroglioma. Glioblastoma showed a significantly higher LRG1 expression than lower-grade glioma (p = 0.0003). High expression of LRG1 was an independent favorable prognostic factor (p = 0.019) in IDH-wildtype glioblastoma and correlated with gross total resection (p = 0.002) and the tumor location on nonsubventricular zone (p = 0.00007). LRG1 demonstrated multiple potential as a diagnostic, prognostic, and regional biomarker for glioblastoma.</description><identifier>ISSN: 0022-3069</identifier><identifier>EISSN: 1554-6578</identifier><identifier>DOI: 10.1093/jnen/nlaa058</identifier><identifier>PMID: 32647893</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Biomarkers, Tumor - metabolism ; Brain cancer ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Child ; Female ; Glioblastoma - metabolism ; Glioblastoma - pathology ; Glioma ; Glycoproteins ; Glycoproteins - metabolism ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Young Adult</subject><ispartof>Journal of neuropathology and experimental neurology, 2020-08, Vol.79 (8), p.873-879</ispartof><rights>2020 American Association of Neuropathologists, Inc. All rights reserved. 2020</rights><rights>2020 by American Association of Neuropathologists, Inc.</rights><rights>2020 American Association of Neuropathologists, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3646-e8bb27ebbc0515bc06a8ff77c379fb42526cd35614aecf58e27686736e98e9a63</citedby><cites>FETCH-LOGICAL-c3646-e8bb27ebbc0515bc06a8ff77c379fb42526cd35614aecf58e27686736e98e9a63</cites><orcidid>0000-0002-6645-7818 ; 0000-0002-7250-457X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32647893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Furuta, Takuya</creatorcontrib><creatorcontrib>Sugita, Yasuo</creatorcontrib><creatorcontrib>Komaki, Satoru</creatorcontrib><creatorcontrib>Ohshima, Koichi</creatorcontrib><creatorcontrib>Morioka, Motohiro</creatorcontrib><creatorcontrib>Uchida, Yasuo</creatorcontrib><creatorcontrib>Tachikawa, Masanori</creatorcontrib><creatorcontrib>Ohtsuki, Sumio</creatorcontrib><creatorcontrib>Terasaki, Tetsuya</creatorcontrib><creatorcontrib>Nakada, Mitsutoshi</creatorcontrib><title>The Multipotential of Leucine-Rich α-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma</title><title>Journal of neuropathology and experimental neurology</title><addtitle>J Neuropathol Exp Neurol</addtitle><description>Abstract
Leucine-rich α-2 glycoprotein 1 (LRG1) is a diagnostic marker candidate for glioblastoma. Although LRG1 has been associated with angiogenesis, it has been suggested that its biomarker role differs depending on the type of tumor. In this study, a clinicopathological examination of LRG1’s role as a biomarker for glioblastoma was performed. We used tumor tissues of 155 cases with diffuse gliomas (27 astrocytomas, 14 oligodendrogliomas, 114 glioblastomas). The immunohistochemical LRG1 intensity scoring was classified into 2 groups: low expression and high expression. Mutations of IDH1, IDH2, and TERT promoter were analyzed through the Sanger method. We examined the relationship between LRG1 expression level in glioblastoma and clinical parameters, such as age, preoperative Karnofsky performance status, tumor location, extent of resection, O6-methylguanine DNA methyltransferase promoter, and prognosis. LRG1 high expression rate was 41.2% in glioblastoma, 3.7% in astrocytoma, and 21.4% in oligodendroglioma. Glioblastoma showed a significantly higher LRG1 expression than lower-grade glioma (p = 0.0003). High expression of LRG1 was an independent favorable prognostic factor (p = 0.019) in IDH-wildtype glioblastoma and correlated with gross total resection (p = 0.002) and the tumor location on nonsubventricular zone (p = 0.00007). LRG1 demonstrated multiple potential as a diagnostic, prognostic, and regional biomarker for glioblastoma.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - pathology</subject><subject>Child</subject><subject>Female</subject><subject>Glioblastoma - metabolism</subject><subject>Glioblastoma - pathology</subject><subject>Glioma</subject><subject>Glycoproteins</subject><subject>Glycoproteins - metabolism</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Young Adult</subject><issn>0022-3069</issn><issn>1554-6578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc1u1DAUhS0EotPCjjWKxAIWmDr-97KM6IA0CAmVdeS4N8RTjz3Yiao-Fi_CM-FoBhYs2Njy0XePju9B6EVL3rXEsMtdhHgZg7VE6Edo1QrBsRRKP0YrQijFjEhzhs5L2RFCDDH8KTpjVHKlDVshfzNC83kOkz-kCeLkbWjS0Gxhdj4C_urd2Pz6iWmzCQ8uHXKFfGzaxpbGNuvgo6-qncYU0nfv6vB7n_Y230FebDbBpz7YMlXtGXoy2FDg-em-QN-uP9ysP-Ltl82n9dUWOya5xKD7niroe0dEK-oprR4GpRxTZug5FVS6WyZkyy24QWigSmqpmASjwVjJLtCbo28N-2OGMnV7XxyEYCOkuXSU07oSosWCvvoH3aU5x5quUoopRTU3lXp7pFxOpWQYukP29Y8PXUu6pYJuqaA7VVDxlyfTud_D7V_4z84rwI_AfQoT5HIX5nvI3Qg2TGNXSyKCKIopoYTo-sKLtIR9fRxL8-H_CX4DC1aglA</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Furuta, Takuya</creator><creator>Sugita, Yasuo</creator><creator>Komaki, Satoru</creator><creator>Ohshima, Koichi</creator><creator>Morioka, Motohiro</creator><creator>Uchida, Yasuo</creator><creator>Tachikawa, Masanori</creator><creator>Ohtsuki, Sumio</creator><creator>Terasaki, Tetsuya</creator><creator>Nakada, Mitsutoshi</creator><general>Oxford University Press</general><general>by American Association of Neuropathologists, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6645-7818</orcidid><orcidid>https://orcid.org/0000-0002-7250-457X</orcidid></search><sort><creationdate>20200801</creationdate><title>The Multipotential of Leucine-Rich α-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma</title><author>Furuta, Takuya ; Sugita, Yasuo ; Komaki, Satoru ; Ohshima, Koichi ; Morioka, Motohiro ; Uchida, Yasuo ; Tachikawa, Masanori ; Ohtsuki, Sumio ; Terasaki, Tetsuya ; Nakada, Mitsutoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3646-e8bb27ebbc0515bc06a8ff77c379fb42526cd35614aecf58e27686736e98e9a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - pathology</topic><topic>Child</topic><topic>Female</topic><topic>Glioblastoma - metabolism</topic><topic>Glioblastoma - pathology</topic><topic>Glioma</topic><topic>Glycoproteins</topic><topic>Glycoproteins - metabolism</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furuta, Takuya</creatorcontrib><creatorcontrib>Sugita, Yasuo</creatorcontrib><creatorcontrib>Komaki, Satoru</creatorcontrib><creatorcontrib>Ohshima, Koichi</creatorcontrib><creatorcontrib>Morioka, Motohiro</creatorcontrib><creatorcontrib>Uchida, Yasuo</creatorcontrib><creatorcontrib>Tachikawa, Masanori</creatorcontrib><creatorcontrib>Ohtsuki, Sumio</creatorcontrib><creatorcontrib>Terasaki, Tetsuya</creatorcontrib><creatorcontrib>Nakada, Mitsutoshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuropathology and experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furuta, Takuya</au><au>Sugita, Yasuo</au><au>Komaki, Satoru</au><au>Ohshima, Koichi</au><au>Morioka, Motohiro</au><au>Uchida, Yasuo</au><au>Tachikawa, Masanori</au><au>Ohtsuki, Sumio</au><au>Terasaki, Tetsuya</au><au>Nakada, Mitsutoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Multipotential of Leucine-Rich α-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma</atitle><jtitle>Journal of neuropathology and experimental neurology</jtitle><addtitle>J Neuropathol Exp Neurol</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>79</volume><issue>8</issue><spage>873</spage><epage>879</epage><pages>873-879</pages><issn>0022-3069</issn><eissn>1554-6578</eissn><abstract>Abstract
Leucine-rich α-2 glycoprotein 1 (LRG1) is a diagnostic marker candidate for glioblastoma. Although LRG1 has been associated with angiogenesis, it has been suggested that its biomarker role differs depending on the type of tumor. In this study, a clinicopathological examination of LRG1’s role as a biomarker for glioblastoma was performed. We used tumor tissues of 155 cases with diffuse gliomas (27 astrocytomas, 14 oligodendrogliomas, 114 glioblastomas). The immunohistochemical LRG1 intensity scoring was classified into 2 groups: low expression and high expression. Mutations of IDH1, IDH2, and TERT promoter were analyzed through the Sanger method. We examined the relationship between LRG1 expression level in glioblastoma and clinical parameters, such as age, preoperative Karnofsky performance status, tumor location, extent of resection, O6-methylguanine DNA methyltransferase promoter, and prognosis. LRG1 high expression rate was 41.2% in glioblastoma, 3.7% in astrocytoma, and 21.4% in oligodendroglioma. Glioblastoma showed a significantly higher LRG1 expression than lower-grade glioma (p = 0.0003). High expression of LRG1 was an independent favorable prognostic factor (p = 0.019) in IDH-wildtype glioblastoma and correlated with gross total resection (p = 0.002) and the tumor location on nonsubventricular zone (p = 0.00007). LRG1 demonstrated multiple potential as a diagnostic, prognostic, and regional biomarker for glioblastoma.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>32647893</pmid><doi>10.1093/jnen/nlaa058</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6645-7818</orcidid><orcidid>https://orcid.org/0000-0002-7250-457X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3069 |
| ispartof | Journal of neuropathology and experimental neurology, 2020-08, Vol.79 (8), p.873-879 |
| issn | 0022-3069 1554-6578 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2423060856 |
| source | MEDLINE; Oxford University Press Journals Current; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Aged, 80 and over Biomarkers Biomarkers, Tumor - metabolism Brain cancer Brain Neoplasms - metabolism Brain Neoplasms - pathology Child Female Glioblastoma - metabolism Glioblastoma - pathology Glioma Glycoproteins Glycoproteins - metabolism Humans Male Middle Aged Prognosis Retrospective Studies Young Adult |
| title | The Multipotential of Leucine-Rich α-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A55%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Multipotential%20of%20Leucine-Rich%20%CE%B1-2%20Glycoprotein%201%20as%20a%20Clinicopathological%20Biomarker%20of%20Glioblastoma&rft.jtitle=Journal%20of%20neuropathology%20and%20experimental%20neurology&rft.au=Furuta,%20Takuya&rft.date=2020-08-01&rft.volume=79&rft.issue=8&rft.spage=873&rft.epage=879&rft.pages=873-879&rft.issn=0022-3069&rft.eissn=1554-6578&rft_id=info:doi/10.1093/jnen/nlaa058&rft_dat=%3Cproquest_cross%3E2423060856%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473772849&rft_id=info:pmid/32647893&rft_oup_id=10.1093/jnen/nlaa058&rfr_iscdi=true |